Medtronic Achieves CoreValve Trial Revisions To Keep Pace With Edwards
This article was originally published in The Gray Sheet
Executive SummaryEnrollment in one section of Medtronic's U.S. pivotal study for its CoreValve transcatheter aortic heart valve will be easier now that FDA has granted conditional approval to modify the trial.
You may also be interested in...
NGM’s Phase II data for FGF19 analog aldafermin shows ability to reduce liver fat and improve fibrosis, but also raises LDL-C. Company says it gets a broader effect this way and can manage the increased cholesterol.